Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma

Seronegative myasthenia gravis is a rare, but potential adverse effect of immune checkpoint inhibition. There have been few but increasing number of cases reported in recent years, and early recognition is important for prompt diagnosis and management. Here, we describe the case of a 65-year-old mal...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandya, Shaunak K, Ulrickson, Matthew, Dong, JiaXi, Willen, Ryan, Pandya, Arati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216640/
https://www.ncbi.nlm.nih.gov/pubmed/34178496
http://dx.doi.org/10.7759/cureus.15174
_version_ 1783710457082675200
author Pandya, Shaunak K
Ulrickson, Matthew
Dong, JiaXi
Willen, Ryan
Pandya, Arati
author_facet Pandya, Shaunak K
Ulrickson, Matthew
Dong, JiaXi
Willen, Ryan
Pandya, Arati
author_sort Pandya, Shaunak K
collection PubMed
description Seronegative myasthenia gravis is a rare, but potential adverse effect of immune checkpoint inhibition. There have been few but increasing number of cases reported in recent years, and early recognition is important for prompt diagnosis and management. Here, we describe the case of a 65-year-old male with metastatic renal cell carcinoma on pembrolizumab diagnosed with new-onset seronegative myasthenia gravis and review literature on its management.
format Online
Article
Text
id pubmed-8216640
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-82166402021-06-24 Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma Pandya, Shaunak K Ulrickson, Matthew Dong, JiaXi Willen, Ryan Pandya, Arati Cureus Neurology Seronegative myasthenia gravis is a rare, but potential adverse effect of immune checkpoint inhibition. There have been few but increasing number of cases reported in recent years, and early recognition is important for prompt diagnosis and management. Here, we describe the case of a 65-year-old male with metastatic renal cell carcinoma on pembrolizumab diagnosed with new-onset seronegative myasthenia gravis and review literature on its management. Cureus 2021-05-22 /pmc/articles/PMC8216640/ /pubmed/34178496 http://dx.doi.org/10.7759/cureus.15174 Text en Copyright © 2021, Pandya et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Neurology
Pandya, Shaunak K
Ulrickson, Matthew
Dong, JiaXi
Willen, Ryan
Pandya, Arati
Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma
title Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma
title_full Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma
title_fullStr Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma
title_full_unstemmed Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma
title_short Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma
title_sort pembrolizumab-associated seronegative myasthenia gravis in a patient with metastatic renal cell carcinoma
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216640/
https://www.ncbi.nlm.nih.gov/pubmed/34178496
http://dx.doi.org/10.7759/cureus.15174
work_keys_str_mv AT pandyashaunakk pembrolizumabassociatedseronegativemyastheniagravisinapatientwithmetastaticrenalcellcarcinoma
AT ulricksonmatthew pembrolizumabassociatedseronegativemyastheniagravisinapatientwithmetastaticrenalcellcarcinoma
AT dongjiaxi pembrolizumabassociatedseronegativemyastheniagravisinapatientwithmetastaticrenalcellcarcinoma
AT willenryan pembrolizumabassociatedseronegativemyastheniagravisinapatientwithmetastaticrenalcellcarcinoma
AT pandyaarati pembrolizumabassociatedseronegativemyastheniagravisinapatientwithmetastaticrenalcellcarcinoma

Ejemplares similares